The Polycythemia Vera drugs in development market research report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Polycythemia Vera. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued products.

GlobalData tracks 21 drugs in development for Polycythemia Vera by 19 companies/universities/institutes. The top development phase for Polycythemia Vera is phase ii with 11 drugs in that stage. The Polycythemia Vera pipeline has 20 drugs in development by companies and one by universities/ institutes. Some of the companies in the Polycythemia Vera pipeline products market are: Incyte, AbbVie and IO Biotech.

The key targets in the Polycythemia Vera pipeline products market include Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2), Transmembrane Protease Serine 6 (Matriptase 2 or Type II Transmembrane Serine Protease 6 or Membrane Bound Mosaic Serine Proteinase Matriptase 2 or TMPRSS6 or EC 3.4.21.), and Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2).

The key mechanisms of action in the Polycythemia Vera pipeline product include Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Inhibitor with five drugs in Filing rejected/Withdrawn. The Polycythemia Vera pipeline products include six routes of administration with the top ROA being Oral and seven key molecule types in the Polycythemia Vera pipeline products market including Small Molecule, and Subunit Vaccine.

Polycythemia Vera overview

Polycythemia vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness, and excessive sweating. The risk of PV increases with age. Treatment includes alkylating agents.

For a complete picture of Polycythemia Vera’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.